NCT02914665已完成2 期
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 308
- 试验地点
- 46
- 主要终点
- Change in NT-proBNP between Baseline and Day 8/Early Discharge
研究概览
简要总结
This is a phase 2 randomized, double-blind, placebo-controlled study to evaluate the cardiac and renal effects of short term treatment with elamipretide in patients hospitalized with congestion due to heart failure
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A history of chronic heart failure for at least 1 month
- •Treated with ≥40 mg/day of furosemide or bumetanide ≥1 mg/day or torasemide ≥10 mg/day for at least 1 month
- •In-hospital observation/admission and treatment for ≤72 hours and primary cause for admission is heart failure with persistent congestion in the opinion of the Investigator (i.e. at least +2 pitting oedema and/or an estimated 8 kg gain in weight over baseline over the past 4 weeks) requiring intravenous loop diuretic therapy
- •Sufficiently severe oedema to justify treatment by an intravenous infusion of furosemide of 10 mg/hour for at least 48 hours
- •Systolic blood pressure >90 mmHg and considered to be haemodynamically stable, in the opinion of the Investigator
- •History of left ventricular ejection fraction (LVEF) ≤40% confirmed in the last 18 months
- •NT-proBNP >1500 pg/ml or BNP >500 pg/ml
- •An eGFR of >30 mL/min/1.73 m2 using the eGFR (mL/min/1.73 m2) = 175 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American)
排除标准
- •Acute coronary syndrome, stroke, or transient ischemic attack (TIA), coronary or peripheral revascularization procedures, valve procedures, OR any major surgical procedure within the previous 6 weeks
- •Invasive cardiac investigation and/or treatment (i.e. coronary angiography, percutaneous coronary intervention [PCI] or surgery) or other surgical procedure planned in the next 4 weeks
- •Use of intravenous radiographic contrast agent within 72 hours prior to screening or planned use during the study
- •Severe, in the investigators opinion, uncorrected valve disease or congenital heart disease as the cause for cardiac decompensation
- •Acute mechanical cause of decompensated heart failure such as papillary muscle rupture
- •Obstructive or infiltrative cardiomyopathy (e.g. amyloid, sarcoid, etc), suspected acute myocarditis, or heart failure related to an untreated metabolic condition (e.g. haemochromatosis)
- •Second or third degree heart block unless the subject has a ventricular pacemaker
- •Atrial fibrillation/flutter with sustained ventricular response of >130 bpm
- •Placement of a ventricular resynchronization device within the previous 6 weeks
- •Treatment or planned treatment with intravenous inotropic agents other than digoxin at any time on this admission
- •Receipt of intravenous vasodilator therapy ≤ 6 hours prior to randomization
- •The presence of any mechanical assist device or listed for or a history of a heart transplant
- •Severe respiratory disease or anticipated need for mechanical respiratory support (i.e. mechanical ventilation)
- •Anuric in the previous 24 hours
- •Haemoglobin <9 g/dL at screening or planned blood transfusions in the next 30 days
- •Serum potassium >5.5 mEq/L
- •Marked proteinuria suggestive of nephrotic syndrome
- •Estimated GFR (eGFR) as per MDRD equation <30 ml/min
- •Serum albumin of < 2.8 g/dL
- •Liver enzymes (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) elevation >5 times the upper limit of normal (ULN)
- •Total bilirubin >2.0 times ULN in the absence of Gilbert's Syndrome
- •Current or planned ultrafiltration, paracentesis, haemofiltration or dialysis
研究组 & 干预措施
20 mg elamipretide
Experimental
20 mg elamipretide once daily for 7 consecutive days
干预措施: elamipretide (Drug)
Placebo
Placebo Comparator
Placebo once daily for 7 consecutive days
干预措施: Placebo (Drug)
结局指标
主要结局
Change in NT-proBNP between Baseline and Day 8/Early Discharge
时间窗: Baseline to Day 8
次要结局
- The patient and physician global assessment is a 7-point scale which either the patient or the physician will assess from 0 to 10 and will be mathematically averaged on a daily basis in order to compare the different averages throughout the study.(Baseline to Day 3 and Day 8)
- The average daily dose of diuretic (furosemide - adjusted for thiazide dose if administered) between baseline and Day 3 and Day 8/Early Discharge(Baseline to Day 3 and Day 8)
- All adverse events, serious adverse events and SUSARs will be summarised per treatment group, namely elamipretide versus placebo, and compared at the end of the study.(Baseline to Day 8)
- Half-life (T1/2)(Baseline to Day 8)
- Area under the concentration - time curve from 0-24 h (AUC 0-24)(Baseline to Day 8)
- Area under the concentration - time curve from 0- infinity (AUC 0-∞)(Baseline to Day 8)
- Peak Plasma Concentration (Cmax)(Baseline to Day 8)
- Number of patients staying in the same functional renal function class measured with MDRD formula compared to the number of patients with decreasing or increasing renal function measured with MDRD formula(Baseline to Day 3 and Day 8)
- Number of patients showing a decrease in body weight compared to baseline as well as number of patients showing either no decrease or an increase in body weight compared to baseline(Baseline to Day 3 and Day 8)
- Calculation of decrease or increase in body weight normalised to the average dose (in mg) of furosemide administered(Baseline to Day 3 and Day 8)
研究者
研究点 (46)
Loading locations...
相似试验
终止
2 期
An Efficacy and Safety Study of Palovarotene for the Treatment of MOExostoses, Multiple HereditaryNCT03442985Clementia Pharmaceuticals Inc.193
终止
2 期
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary GeneralizationRefractory EpilepsyNCT04153175Cerebral Therapeutics LLC30
招募中
2 期
Study of Stapokibart Injection in Patients With Allergic RhinitisAllergic RhinitisNCT06525597Keymed Biosciences Co.Ltd120
已完成
2 期
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)Hypertension, PulmonaryNCT04945460Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA164
已完成
2 期
A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and SarcopeniaSarcopeniaLiver CirrhosisNCT04874350Lipocine Inc.30